A clinical utility study claimed use of the Afirma Gene Expression Classifier, developed by Veracyte Inc., can significantly reduce unnecessary surgeries in thyroid cancer diagnoses. The study was published in Cancer Cytopathology.
After Karen Knudsen departed from the American Cancer Society late last year, the question of where she will end up becoming the fodder for cocktail party chatter throughout oncology.
